VB Spine, LLC announced on 29 September 2026 that FDA granted Breakthrough Device Designation to ScolimiR-3D, a blood test designed to identify which adolescents with idiopathic scoliosis are likely to progress to a severe spinal curve. The designation is a first for a predictive, blood-based risk-assessment test in the disease, and it arrives fifteen months after VB Spine said it would fund the underlying research toward exactly this kind of FDA submission.
ScolimiR-3D's case, in four numbers
Figures from Khatami et al., Scientific Reports (2025), and VB Spine's 29 September 2026 announcement.
From a Stryker carve-out to a diagnostics bet
From a 2001 lab to a 2026 designation
- 2001
Research begins
Dr. Alain Moreau begins researching the molecular genetics of adolescent idiopathic scoliosis at CHU Sainte-Justine in Montreal.
- 2006
Early proof of concept
Moreau's lab publishes early proof-of-concept work on blood-based biomarkers of AIS progression.
- February 2025
Validation study published
Khatami et al. publish the 116-patient study behind ScolimiR-3D's six-microRNA panel in Scientific Reports, reporting 100% sensitivity and specificity.
- 1 April 2025
VB Spine formed
Viscogliosi Brothers completes its acquisition of Stryker's U.S. spinal-implants business, forming VB Spine as a standalone private company.
- 3 June 2026
Research funding announced
VB Spine announces it will fund Dr. Moreau's continued research toward clinical validation, FDA submission and commercialization of the blood test that became ScolimiR-3D.
- 29 September 2026
Breakthrough Device Designation
FDA grants ScolimiR-3D Breakthrough Device Designation, fifteen months after VB Spine's funding announcement.
- Ahead
Marketing authorization still pending
ScolimiR-3D still needs a separate FDA marketing authorization, such as a 510(k) or De Novo clearance, before it can be sold; VB Spine has not published a filing timeline.
What FDA's breakthrough label does, and doesn't, grant
Breakthrough Device Designation is a development accelerator, not a sales license. It gives VB Spine more frequent, more senior interactions with FDA reviewers and a commitment to prioritized review once the company files for marketing authorization — typically a 510(k) or De Novo pathway for a test like this. FDA does not publish a public database of individual Breakthrough Device grants the way it does cleared 510(k)s or approved PMAs, so unlike a clearance number, this designation has no public FDA record to check against; VB Spine's own announcement, corroborated by independent trade-press coverage, is the record this article relies on.
“Receiving FDA Breakthrough Device Designation is a significant milestone for this technology and for the future of scoliosis care. ScolimiR-3D will provide physicians with insights that support earlier, more informed decision-making.” Marc Viscogliosi, Co-Chief Executive Officer, VB Spine — 29 September 2026 announcement
Six microRNAs, one risk score
ScolimiR-3D measures six circulating microRNAs — miR-1-3p, miR-19a-3p, miR-19b-3p, miR-133b, miR-143-3p and miR-148b-3p — from a standard blood draw taken at or near an adolescent's scoliosis diagnosis. In the published validation study, researchers followed 116 AIS patients from diagnosis to skeletal maturity, then used a Random Forest model built on this six-gene panel to classify who had progressed to a severe curve (a Cobb angle of 45 degrees or more). VB Spine positions the result as a tool to help physicians and families decide on bracing intensity and monitoring frequency earlier than today's standard approach, which relies on repeated X-rays over years rather than a single blood draw at diagnosis.
What a blood test changes for AIS care
A blood draw, not an X-ray
ScolimiR-3D measures six circulating microRNAs from a standard blood draw, rather than tracking curve progression through repeated radiographs — avoiding the cumulative radiation exposure of following a child with X-rays for years.
Built for the diagnosis visit
VB Spine positions the test for use at or near initial AIS diagnosis, aiming to help physicians and families decide on bracing and monitoring intensity earlier than today's wait-and-rescan approach allows.
A validated accuracy rival tools lacked
The 116-patient study behind ScolimiR-3D reported 100% sensitivity and specificity for predicting progression to a severe curve — a bar the earlier genetic ScoliScore test, now discontinued, reportedly did not clear on independent reanalysis.
What a scoliosis risk test is worth
$1.26B → $1.29B
Global scoliosis market, 2025 to 2026, as sized by The Business Research Company.
Sources: The Business Research Company, Scoliosis Global Market Report
Regulatory News outlook
A single predictive blood test won't move a market sized in the low billions on its own, but we'd expect ScolimiR-3D's entry to expand the diagnostic slice of scoliosis care — creating demand for earlier bracing decisions — rather than compete for share of existing bracing or surgical spend.
How we got here: The Business Research Company's Scoliosis Global Market Report puts the category at $1.26 billion in 2025 and $1.29 billion in 2026, a 2.4% annual growth rate; we treat a new predictive-diagnostic category as additive to that figure rather than substitutional, since AIS risk-assessment testing is not currently a line item most scoliosis-market reports break out separately.
ScolimiR-3D against how AIS risk is judged today
| Test or tool | Sample | What it measures | Status |
|---|---|---|---|
| ScolimiR-3D (VB Spine) | Blood draw (6 circulating microRNAs) | Risk of progressing to a severe curve (≥45°) by skeletal maturity | FDA Breakthrough Device Designation, Sep 2026 |
| Cobb angle + Risser sign (standard of care) | Spinal X-ray, repeated every 4–6 months | Current curve magnitude and skeletal maturity | Standard of care under Scoliosis Research Society guidelines |
| ScoliScore (Axial Biotech / Transgenomic) | Cheek-swab DNA, 53-marker genetic panel | Genetic risk score for progression beyond 40° | Discontinued; independent reanalysis reportedly did not replicate its performance |
From the cited validation study, published clinical-practice guidelines and reporting on ScoliScore's discontinuation; not a head-to-head clinical comparison.
What ScolimiR-3D still has to clear
Several details that would usually anchor a company profile are not yet public: VB Spine has not disclosed its own headquarters city (its press releases are datelined New York, where parent Viscogliosi Brothers is based), the dollar amount of its June 2026 research-funding commitment, or a filing timeline for the marketing authorization ScolimiR-3D still needs before it can be sold. What is confirmed is the designation itself, the validation data behind it, and a company with the scale — a spinal-implant business it describes as the largest privately held in its category — to fund the test the rest of the way.
- Designation: FDA Breakthrough Device Designation, announced 29 September 2026 — the first such designation for a predictive AIS risk-assessment blood test.
- What breakthrough status does: It speeds FDA interactions and prioritizes review for ScolimiR-3D's eventual marketing-authorization filing; it is not itself a clearance or approval to sell the test.
- Company scale: VB Spine describes itself as the largest privately held spine company, operating the implant and robotics-adjacent portfolio it inherited from Stryker's former U.S. spine business.
- Not yet public: VB Spine's own headquarters city, the dollar amount of its June 2026 research-funding commitment, and a timeline for ScolimiR-3D's marketing-authorization filing.
Sources & further reading
- VB Spine, announcement of FDA Breakthrough Device Designation for ScolimiR-3D, 29 September 2026 (via Ortho Spine News). orthospinenews.com
- ODT Magazine, “VB Spine's Scoliosis Blood Test Earns FDA Breakthrough Nod.” odtmag.com
- Contemporary Pediatrics, coverage of the ScolimiR-3D Breakthrough Device Designation. contemporarypediatrics.com
- Khatami N, et al., “Genome-wide profiling of circulating microRNAs in adolescent idiopathic scoliosis and their relation to spinal deformity severity, and disease pathophysiology,” Scientific Reports 15, 5305 (2025). nature.com
- Becker's Spine Review, “VB Spine funds research for scoliosis blood test.” beckersspine.com
- FierceBiotech, “Stryker spins off spinal implant business to Viscogliosi Brothers-owned VB Spine.” fiercebiotech.com
- Stryker, press release on completion of the sale of its U.S. spinal implants business, April 2025. investors.stryker.com
- Becker's Spine Review, “VB Spine pushes into the market: 5 things to know.” beckersspine.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What exactly did FDA grant VB Spine on September 29, 2026?
Breakthrough Device Designation for ScolimiR-3D, a blood test intended to predict which adolescents with idiopathic scoliosis are at risk of progressing to a severe spinal curve. The designation speeds FDA's interactions with VB Spine during development and review; it is not itself a clearance or approval to sell the test.
How does the test work?
It measures six circulating microRNAs (miR-1-3p, miR-19a-3p, miR-19b-3p, miR-133b, miR-143-3p and miR-148b-3p) from a standard blood draw. In a 116-patient validation study published in Scientific Reports, a model built on this panel predicted progression to a severe curve with 100% sensitivity and specificity.
Is VB Spine a scoliosis-only company?
No. VB Spine is primarily a spinal-implant and surgical-technology business, formed in April 2025 when the Viscogliosi Brothers family office acquired Stryker's former U.S. spinal-implants portfolio. ScolimiR-3D is a newer diagnostics program, built on research VB Spine began funding in June 2026.
When will ScolimiR-3D actually be available to order?
Not yet. Breakthrough Device Designation does not authorize marketing; VB Spine still needs a separate FDA marketing authorization (such as a 510(k) or De Novo clearance) before the test can be sold, and the company has not published a timeline for that filing.
